Tuesday, May 27, 2008

Novartis' MS drug Extavia gains approval in EU

Novartis' MS drug Extavia gains approval in EU
The Money Times - Mumbai,Maharashtra,India
... means we are able to offer the MS community a current standard of care while preparing for the introduction of innovative therapies such as FTY720. ...
See all stories on this topic

Novartis MS Drug, Rival to Bayer's, Wins Approval (Update1)
Bloomberg - USA
By Dermot Doherty May 26 (Bloomberg) -- Novartis AG, Switzerland's second- biggest drugmaker, won European regulatory approval for its Extavia multiple ...
See all stories on this topic

UPDATE 1-Novartis' MS drug gets approval in EU
Reuters - USA
Extavia will give Novartis an important presence in MS treatment before the submission of its once-daily therapy FTY720 (fingolimod). ...
See all stories on this topic

Extavia® Approved In European Union For Treatment Of Multiple ...
ABN Newswire (press release) - Sydney,NSW,Australia
By the end of 2009, Novartis also plans to file for approval of the innovative oral therapy FTY720 (fingolimod). Results of an ongoing Phase II study ...
See all stories on this topic

Ask the Expert - Interrogez un spécialiste

MS Answers


Dr. O'Connor

Neurologist, MS Clinic at St. Michael's Hospital in Toronto, ON
View BIO

Q :
If a person dies having been diagnosed with MS, what data is collected and by who?
A :
That all depends on whether the body of the person with MS is subject to a medical examination after death (an autopsy). The decision to request an autopsy usually comes from the next of kin, although in rare circumstances the coroner can order one. Religious practice, custom, and the deceased person's wishes in this regard are all important factors in what happens. Most of the time, an autopsy is not performed.
5/26/2008 10:01:02 PM
More answers from Dr. Paul O'Connor
More answers in the category: Research
For more information related to this topic, please click Research Page



Tysabri faces uphill battle in Crohn's disease
Reuters - USA
O: Quote, Profile, Research) to hit its stated goal of 100000 patients on Tysabri by 2010. But it faces an uphill battle as a treatment for the bowel ...
See all stories on this topic

Elan mulls separate listing for EDT unit -report
Reuters - USA
... in February that Elan was considering splitting its bio-pharmaceuticals arm, which markets its flagship multiple sclerosis drug Tysabri, from EDT. ...
See all stories on this topic

Elan confident of posting healthy profits in two years' time
Pharma Times (subscription) - London,UK
Ireland’s Elan Corp has reiterated its faith in reaching a target of 100000 patients for its multiple sclerosis drug Tysabri by the end of 2010. ...
See all stories on this topic

Novartis MS Drug, Rival to Bayer's, Wins EU Approval (Update3)
Bloomberg - USA
... Idec Inc.'s Avonex, Merck Serono SA's Rebif, Teva Pharmaceutical Industries Ltd.'s Copaxone and Elan Corp. and Biogen's Tysabri for share of the MS market.
See all stories on this topic


Post a Comment

Links to this post:

Create a Link

<< Home